At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Histologically confirmed high-grade serous epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer
- ✓Newly diagnosed advanced disease (FIGO stage III or IV)
- ✓Candidate for first-line platinum-based chemotherapy
- ✕Recurrent high-grade serous epithelial ovarian, fallopian tube, or peritoneal cancer
- ✕Non-epithelial or borderline ovarian cancer
- ✕Other active tumor that may interfere with ovarian cancer treatment or significantly impact prognosis
- ✕Exclusive palliative setting
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HRD Tests for Ovarian cancER
In Brief
A Phase 2 clinical trial evaluating tests to determine HRD status for Ovarian Cancer. Currently recruiting, targeting 88 participants across 4 sites.
Signals
Detailed Summary
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy. To determine HRD status, 2 separate tests will be performed in the study: 1. Giscar assay : developed by the sponsor 2. myChoice assay If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations
Study Details
Timeline
Interventions
Test Giscar AND test myChoice will be performed. If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations